Pieris Pharmaceuticals, Inc.
EXHIBIT 10.62
000 Xxxxxxxx Xxxxxx, Xxxxx 00
Boston, MA 02110
x0-000-000-0000
xxx.xxxxxx.xxx
December 11, 2023
NOTICE OF EXTENSION NO.1 TO CONSULTING AGREEMENT
The Consulting Agreement (“Agreement”), entered into between Pieris Pharmaceuticals, Inc. and Pieris Pharmaceuticals GmbH (collectively, “Pieris”) and Xxxxx Xxxxx located at 000 Xxxxxxxx Xxxxxx, Xxx. 000, Xxxxxx, XX 00000 (hereinafter the “Advisor”), with an effective date of September 11, 2023, expires on December 11, 2023. Pursuant to Section 10 of the Agreement, this letter extension (“Extension No. 1”) hereby confirms both Parties’ agreement to extend the Term of the Agreement by an additional three (3) months. This Extension No. 1 shall form an integral part of the Agreement. The provisions of the Agreement that are not amended or deleted by this Extension No. 1 remain unchanged and in full force and effect. All capitalized terms used herein and not specifically defined will have the meanings ascribed to such terms in the Agreement.
This Extension No. 1 is executed, effective as of the date at the top of this letter, by the Parties’ duly authorized representatives.
Pieris Advisor
By: ___/s/ Xxx Xxxxx By: /s/ Xxxxx Xxxxx
Name: Xxx Xxxxx ________ Name: Xxxxx Xxxxx
Title: ____Chief Financial Officer_ Title: ____________________________
